Sam Brusco, Associate Editor11.15.23
Sunrise, a company focused on home sleep diagnostics, has gained additional aggregate investment of $6 million from the Alexa Fund and French healthcare investor UI-Investissement. This latest funding brings the company’s total annual funds raised to $24 million.
The company recently earned €17 million in funding, led by Kurma Partners and the European Innovation Council (EIC Fund).
The company already has had quite a year, boasting two U.S. Food and Drug Administration (FDA) approvals and renewed CE certification under the (MDR) Medical Device Regulation in Europe. Sunrise also won the 2022 SleepTech Award from the National Sleep Foundation.
The company’s approach to monitoring sleep focuses on mandibular jaw movements via an eight-gram sensor placed on the chin. Sunrise said that much like the diaphragm supports breathing when asleep, jaw movements are also critical for precision sleep diagnosis.
The device further measures “respiratory effort”, which Sunrise says is commonly overlooked and can help distinguish between central and obstructive sleep apnea. It also tracks “respiratory effort burden” a new metric linked to fatigue, Type 2 diabetes, and hypertension.
"Sleep disorders are a global concern, and we're proud to be an investor in Sunrise and support their innovative approach to aid in the diagnosis of sleep-related breathing disorders," Alexa Fund director Paul Bernard told the press. "Their technology, designed for multi-night testing that leverages key sleep metrics, has the potential to redefine sleep apnea diagnosis and care for millions of people suffering from sleep disorders worldwide."
The company recently earned €17 million in funding, led by Kurma Partners and the European Innovation Council (EIC Fund).
The company already has had quite a year, boasting two U.S. Food and Drug Administration (FDA) approvals and renewed CE certification under the (MDR) Medical Device Regulation in Europe. Sunrise also won the 2022 SleepTech Award from the National Sleep Foundation.
The company’s approach to monitoring sleep focuses on mandibular jaw movements via an eight-gram sensor placed on the chin. Sunrise said that much like the diaphragm supports breathing when asleep, jaw movements are also critical for precision sleep diagnosis.
The device further measures “respiratory effort”, which Sunrise says is commonly overlooked and can help distinguish between central and obstructive sleep apnea. It also tracks “respiratory effort burden” a new metric linked to fatigue, Type 2 diabetes, and hypertension.
"Sleep disorders are a global concern, and we're proud to be an investor in Sunrise and support their innovative approach to aid in the diagnosis of sleep-related breathing disorders," Alexa Fund director Paul Bernard told the press. "Their technology, designed for multi-night testing that leverages key sleep metrics, has the potential to redefine sleep apnea diagnosis and care for millions of people suffering from sleep disorders worldwide."